Additional file 3: Table S3. A) Peptides with a statistical significant (p < 0.05) urinary abundance (m/z area) according to the Grade. B) Peptides with a statistically significant (p < 0.05) urinary abundance (m/z area) compared to CTRLs and at different Grade (1, 2, 3 and 4). Up/down refer to the over/under representation of the peptide in ccRCC patients compared to control subjects
Additional file 7: Figure S2. Performance of the urinary proteome profiling workflow in peptide leve...
Additional file 4. Table S3. Coefficient of variation (CV%) values of the sums of logarithm base two...
Additional file 3: Figure S3. The therapeutic effect of peptide2 in the xenograft model. (a) Schemat...
Additional file 2: Table S2. A) Peptides with a statistically significant (p < 0.05) urinary abund...
Additional file 1: Table S1. Peptides with a statistically significant (p < 0.05) urinary abundanc...
Additional file 4: Table S4. Peptides with a statistically significant (p > 0.05) urinary abundanc...
Background: Several promising biomarkers have been found for RCC, but none of them has been used in ...
Background: Several promising biomarkers have been found for RCC, but none of them has been used in ...
Figure S4. a) Contingency table showing the frequency distribution of CCDC6 intensity IHC staining v...
Additional file 3. Table S2. The number of identified and quantified proteins in individual samples ...
Additional file 5: Table S5. Identification of MALDI signals varied according to tumour size, pT o...
Figure S3. Correlations between 5mC score and clinicopathological parameters. A) In the full PC set ...
Figure S1. Flow chart illustrating the sample inclusion/exclusion process in malignant cores. A) 5mC...
Distribution of 5hmC scores by clinicopathological parameters and BCR status in ERG+ PC. ERG+ subset...
Additional file 2: Table S2 Average Chi Square value per gene symbol for ovarian cancer versus norma...
Additional file 7: Figure S2. Performance of the urinary proteome profiling workflow in peptide leve...
Additional file 4. Table S3. Coefficient of variation (CV%) values of the sums of logarithm base two...
Additional file 3: Figure S3. The therapeutic effect of peptide2 in the xenograft model. (a) Schemat...
Additional file 2: Table S2. A) Peptides with a statistically significant (p < 0.05) urinary abund...
Additional file 1: Table S1. Peptides with a statistically significant (p < 0.05) urinary abundanc...
Additional file 4: Table S4. Peptides with a statistically significant (p > 0.05) urinary abundanc...
Background: Several promising biomarkers have been found for RCC, but none of them has been used in ...
Background: Several promising biomarkers have been found for RCC, but none of them has been used in ...
Figure S4. a) Contingency table showing the frequency distribution of CCDC6 intensity IHC staining v...
Additional file 3. Table S2. The number of identified and quantified proteins in individual samples ...
Additional file 5: Table S5. Identification of MALDI signals varied according to tumour size, pT o...
Figure S3. Correlations between 5mC score and clinicopathological parameters. A) In the full PC set ...
Figure S1. Flow chart illustrating the sample inclusion/exclusion process in malignant cores. A) 5mC...
Distribution of 5hmC scores by clinicopathological parameters and BCR status in ERG+ PC. ERG+ subset...
Additional file 2: Table S2 Average Chi Square value per gene symbol for ovarian cancer versus norma...
Additional file 7: Figure S2. Performance of the urinary proteome profiling workflow in peptide leve...
Additional file 4. Table S3. Coefficient of variation (CV%) values of the sums of logarithm base two...
Additional file 3: Figure S3. The therapeutic effect of peptide2 in the xenograft model. (a) Schemat...